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ABSTRACT 
Poly(ADP-ribosylation) (PARylation) is an important post-translational modification that 
maintains genomic stability in a cell. Engaging in important cellular processes such as DNA 
repair and cell death signaling, PARylation has gathered considerable interest as a target for 
genotoxic chemotherapy against cancer cells. To this end, various Poly(ADP-ribose) Polymerase 
(PARP) inhibitors have been developed to induce sensitivity to genotoxic stress in BRCA-
mutated cancer cells, and Poly(ADP-ribose) Glycohydrolase (PARG) inhibition is investigated 
as an alternate pathway to PARP inhibition in genotoxic chemotherapy. However, little is known 
about the exact mode of interaction between PAR and different proteins mainly due to the fact 
that PARP produces polydisperse mixtures of PAR through a heterogeneous modification 
process. To tackle these problems, a controlled enzymatic synthesis pathway of PAR has been 
investigated through the use of masked β-NAD+ derivatives that can homogenously and 
monomerically modify PARP. In order to verify its ability to modify PARP, a sample of 
proparagyl-β-NAD+ derivative was used in an automodification assay with hTNKS-1. In addition, 
a PARG inhibitor prodrug in the form of an alanine-ester-masked ADP-HPM was developed as a 
cell-permeable PARG inhibitor to investigate its effect in a whole cell. In order to verify its 
activity, an in vitro experiment of the enzymatic cleavage of its masking group with HINT-1 was 
performed and the results were analyzed via LC/MS. 
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Figure 1.1. PARylation cycle with minor DNA damage. In case the extent of damage is 
minor, PARP produces PAR from β-NAD+ to recruit DNA repair factors. 
CHAPTER 1 
PAR-CYCLE AS TARGET FOR CANCER TREATMENT 
 
1.1. Introduction: The PAR-cycle 
Poly(ADP-Ribosylation) (PARylation) is an important post-translational modification 
that governs important cellular processes, ranging from DNA repair, transcription, and telomere 
maintenance to cell division and cell death.
1-4
 Figures 1.1 and 1.2 illustrate the outline of the 
general process: When DNA damage is detected, Poly(ADP-Ribose) Polymerase (PARP) binds 
to the damage site to release chemical signals in the form of PARylation, where β-NAD+ is 
consumed to polymerize into Poly(ADP-Ribose) (PAR). These polymers act as molecular 
scaffolds for recruitment of DNA repairing factors such as XRCC-1 to the DNA damage site. 
Once DNA damage is repaired, Poly(ADP-Ribose) Glycohydrolase (PARG) cleaves PAR from 
the inactivated PARP complex and further degrades PAR down to monomeric ADP-Ribose units.  
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Figure 1.2. PARylation cycle with severe DNA damage. When the DNA damage is severe, 
PAR is overproduced and cleaved by PARG. The resulting long-chain PAR interacts with the 
cell’s mitochondria to trigger PAR-mediated cell death known as PARthanatos. 
 
On the other hand, if the DNA damage is severe and beyond repair, PARP overproduces 
PAR, resulting in longer chains of PAR that act as cell death signals by interacting with the 
Apoptosis Inducing Factor (AIF) of the cell’s mitochondria; thus, triggering a sequence of cell 
death known as PARthanatos.
5
 Due to its ability to induce cell death under increased genotoxic 
stress, manipulation of the PAR-cycle has been investigated as a means to supplement genotoxic 
chemotherapy for cancer.  
 
1.2. PARP-inhibition in cancer treatment 
Various PARP inhibitors have been developed to treat patients with BRCA mutations
6
 
(Figure 1.3). In normal cells, PARP-1 is recruited to the DNA damage site to perform Base-
Excision Repair (BER) on Single-Strand Breaks (SSBs). In PARP-inhibited cells, the inability to  
3 
 
 
perform BER results in the conversion of SSBs to Double-Strand Breaks (DSBs). To repair 
DSBs, PARP1 binds to the damage site to recruit proteins MRE11 and NBS1 to carry out the 
error-free repair mechanism known as Homologous Recombination (HR)
7,8
 and PARylate a key 
protein, BRCA1, that contributes to HR-mediated DSB repairs.
9
 Therefore, in BRCA1/2 mutated 
patients, PARP inhibition can prevent HR-activation and force cells to follow an error-prone 
repair pathway known as Non-Homologous End Joining (NHEJ), which results in increased 
genotoxic sensitivity and the eventual cell death. Initial studies have shown promising results for 
PARP inhibitors in treatment of ovarian cancer and, as of 2015, PARP inhibitor Olaparib, 
Figure 1.3. Mechanism of cell death via PARP inhibition. A) PARP inhibitors are used in 
conjunction with DNA damaging agents to induce cell death in BRCA-mutated cells. Loss of 
PARP function prevents DNA damage repair via base excision, and loss of BRCA function 
prevents high-fidelity repair such as homologous recombination. This causes cells to follow a 
low-fidelity error-prone repair pathway, leading to increased sensitivity to genotoxic stress. 
B) Currently available PARP inhibitors. Olaparib is FDA-approved for ovarian/breast cancer 
patients with BRCA mutations. 
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distributed by AstraZeneca, has been approved by the US Food and Drug Administration as a 
fourth-line monotherapy for ovarian cancer in BRCA1/2 mutated patients.
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1.3. Investigations in PAR and PARG inhibition 
Despite these promising results several questions remain in the field of PAR research and 
its application to cancer treatment: How does PAR interact with PAR-binding proteins? What is 
the chemical nature of the bond between PAR and its modification sites? How many PAR 
modification sites exist on PARP? To explore these questions, there is a need to develop a means 
to produce defined-length PAR as well as a controlled method of PAR-modification on PARP. 
Additionally, are there other means to manipulate the PARylation cycle to induce cell 
death via PARthanatos? Given that severe DNA damage results in overproduction of long-chain 
PAR which can act as a death signal,
10
 inhibiting PARG may delay the degredation of long-chain 
PAR to small-chain PAR or ADP-ribose monomers as well as contribute to the inactivation of 
PARP by saturating its modification sites with PAR. To this end, investigations have been 
carried out on the possibilities of PARG inhibition as an alternative to PARP inhibition.  
 
1.3.1. Enzymatic and chemical synthesis of PAR 
Upon detection of DNA damage, PARP binds to the DNA damage site via its zinc fingers 
and produces PAR of various lengths through a process known as automodification during which 
PARP enzymatically produces PAR on other PARP molecules of close proximity. Figure 1.4 
shows the heterogeneous pattern of PAR production by PARP-1. While some members of the 
PARP family are known to mono-ADP-ribosylate proteins, the lengths of PAR produced by 
PARP can range anywhere from 2 units to 200 units
 
and may have branching units.
11
 While 
polydisperse samples of enzymatically-synthesized PAR are commercially available, defined-
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length samples of PAR are currently unavailable through such means. 
 In 2015, Lambrecht and co-workers succeeded in chemically synthesizing di-ADP-ribose, 
the first case of a successful chemical synthesis of defined-length PAR unit in literature.
12
 
Starting with adenosine and ribose, through 30 steps Lambrecht and co-workers were able to 
synthesize di-ADP-ribose in an overall yield of 15%. The same year, Kistemaker and co-workers 
reported in literature a method to synthesize defined-length PAR units via solid phase support.
13
 
Though the number of steps required to produce di-ADP ribose was shorter, the overall yield of 
Figure 1.4. Heterogeneous modification pattern of PARP. A) Automodification of PARP 
follows a heterogeneous pattern where each PAR unit can range anywhere from 2 to 200 ADP-
ribose units.
11
 B) Automodification of PARP follows a heterogeneous pattern where each PAR 
unit can form branches of irregular patterns. 
≡ 
A) 
B) 
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the process was less than 1%, and the final product had a methyl acetal protecting group that 
could not be removed. Since then, there have been no reported cases in the literature of 
successful chemical synthesis of PAR units of longer length (greater than 5 ADPr units). 
As described previously, PAR plays an important role in various cellular processes, 
ranging from DNA damage repairs to triggering cell death known as PARthanatos. Despite its 
pivotal role in such processes, little is known about the interaction between PAR and various 
proteins. To begin with, the number of PAR modification sites on PARP and the nature of the 
chemical bond between these modification sites and PAR have long been debated.
14-16
 With the 
heterogeneous modification pattern of PAR on PARP, the exact number of modification sites on 
PARP as well as the chemical bond of the modification cannot be elucidated. Furthermore, there 
needs to be a means to access defined-length PAR of longer length. With the available chemical 
methods developed currently, producing dimers and short-length PAR may be plausible, but 
producing medium-to-long-length PAR is impractical due to the low overall yields of the 
synthesis and required number of steps to chemically synthesize PAR.  
 
1.3.2. Development of PARG Inhibitors 
 As discussed previously, several PARP inhibitors have been developed and are currently 
being evaluated in clinical trials for cancer therapy. The inhibition of a related enzyme, PARG, 
has also been suggested
17,18
 to achieve similar effects albeit via a different mechanism (Figure 
1.5). The strategy of inducing cell death through enhanced sensitivity to genotoxic stress via 
PARG inhibition has garnered considerable interest for several reasons: PARG activity plays a 
key role in the initiation of cell death and the enzyme itself is an attractive pharmacological 
target due to its low cellular abundance, which is approximately 2,000 molecules per cell.
17
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However, investigations of PARG inhibition are largely thwarted by the lack of a potent, specific, 
and cell-permeable inhibitor.  
In 1995, Jacobson and co-workers reported a potent PARG inhibitor known as ADP-HPD 
(1.1) with an IC50 value of 0.12 μM.
19
 Its potency and relatively accessible synthetic route of 12 
steps makes it an ideal benchmark of PARG inhibition and an attractive target of studying PARG 
inhibition. However, the pyrophosphate moiety and multiple polar functional groups render the 
molecule extremely hydrophilic and therefore not cell-permeable. Jacobson and co-workers have 
tested the inhibition of bovine PARG (bPARG) by modified ADP-HPD (1.2, 1.3). While both 
molecules exhibited inhibition of bPARG in vitro, no cell-permeability assay was carried out to 
show that 1.3 can permeate cells.
20 
 
 
Figure 1.5. PARylation cycle with severe DNA damage. When the DNA damage is severe, 
PAR is overproduced and cleaved by PARG. The resulting long-chain PAR interacts with the 
cell’s mitochondria to trigger PAR-mediated cell death known as PARthanatos. 
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Compound PARG IC50 (μM) 
 
ADP-HPD (1.1) 
0.12
19
 
 
ADP-HPM (1.2) 
3.07 (bPARG)
20
 
 
1.3 
9.5 (bPARG)
20
 
 
 
Mono-galloyl glucose (1.4) 
0.95
21
 
 
 
RBPI3 (1.5) 
5.8
17
 
 
 
Phenolic hydrazide hydrazones (1.6) 
1.0
22
 
 
Table 1.1. PARG inhibitors and their potency. 
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Ever since the discovery of ADP-HPD, several other PARG inhibitors have been 
developed, with their inhibition effects shown in table 1.1.
17,19-22
 While none of them show 
potency as strong as that of ADP-HPD, no studies have been carried out to determine the cell 
permeability of the reported PARG inhibitors. In order to establish the efficacy of PARG 
inhibition in causing programmed cell death, a cell-permeable small molecule inhibitor of PARG 
needs to be developed.  
 
1.4. Summary and outlook 
Manipulation of the PAR cycle through PARP/PARG inhibition has become an attractive 
target for cancer therapy. However, several important questions remain in the field that arise 
from the lack of appropriate chemical tools to investigate the chemical biology behind the PAR-
cycle. The lack of means to homogenously modify PAR has led to the inability to investigate the 
chemical nature of the PAR-PARP modification site bond and the count of the modification sites. 
The lack of means to control the modification pattern of PAR results in the lack of accessibility 
to defined-length PAR for protein assays. With currently available chemical means, one can 
synthesize dimers and trimers of PAR, but synthesizing PAR molecules any longer than trimers 
requires a large number of synthetic steps and consequently suffers from low overall yields. 
There is a need to control the modification pattern of PAR to investigate means to synthesize 
defined-length PAR. 
Additionally, the lack of cell-permeable PARG inhibitors thwarts investigation of PARG 
inhibition as an alternative to PARP inhibition in genotoxic chemotherapy. While several potent 
PARG inhibitors have been developed, they display lack of cell permeability or conclusive 
studies have not yet been carried out for their cell permeability. In order to demonstrate PARG 
10 
 
inhibition as a plausible supplementary method to genotoxic chemotherapy, in vivo studies of 
PARG inhibition need to be carried out. Therefore, there is an urgent need to develop cell-
permeable PARG inhibitors that can demonstrate as potent inhibition as ADP-HPD. 
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CHAPTER 2 
SYNTHESIS OF DEFINED-LENGTH PAR 
The enzymatic synthesis experiment of PAR by PARP has been planned out with 
Michael Lambrecht. Portions of the synthetic work of masked β-NAD+ derivatives and biological 
assay by human Tankyrase-1 were performed in collaboration with Michael Lambrecht.  
 
2.1. Controlled enzymatic synthesis of PAR 
It is suggested that PAR interacts with various proteins that play important roles in 
cellular processes such as DNA repair and cell death; however, little is known about the specifics 
of the interaction between PAR and relevant proteins. To begin with, it is uncertain how PAR 
modifies PARP and how many modification sites there are on PARP. Furthermore, relationships 
between length of PAR and interaction with various proteins haven’t been established. Most of 
these questions couldn’t be answered due to the heterogeneous automodification pattern of PAR 
on PARP. If there were a means to homogenously modify PARP with PAR, not only could we 
answer the questions of PARP modification but also produce defined-length PAR to carry out 
bioassays to establish relationships between size of the polymer and its activity. To this end, we 
suggest a controlled enzymatic synthesis experiment of PAR. 
  As discussed in chapter 1, chemical synthesis of defined-length PAR is an arduous and 
inefficient way to produce PAR of desired length due to the number of steps required (>30 steps) 
and low overall yield (<15%).
1,2
 On the other hand, it is impossible to produce defined-length 
PAR through enzymatic synthesis with the original β-NAD+ feedstock because use of β-NAD+ 
results in a heterogeneous modification pattern.
3
 Since PARylation proceeds on the 2’-hydroxyl 
group of adenosine on ADP-ribose, using a modified β-NAD+ derivative with the 2’-hydroxyl 
13 
 
group in question masked can stop the modification at a monomeric level and thus 
homogenously modify PARP. If the masking group can be removed easily (e.g. through 
photochemical cleavage), this monomeric modification can be utilized to synthesize defined-
length PAR 
 
 
  
β-NAD 
 
PARP 
digestion 
= Masking group 
= ADPr units 
= PARP 
 
PG-NAD 
 
Deprotection 
 
PG-NAD 
 
Cleavage 
 
PARP 
digestion 
Regular, defined length PAR 
 
A) 
B) 
Figure 2.1. Controlled enzymatic synthesis of PAR. A) Traditionally, PAR is obtained by 
feeding PARP with regular β-NAD+ as feedstock; however, this produces a polydisperse 
mixture of PAR with varying lengths. B) In this experiment, A masked β-NAD+ derivative 
can be used to end the modification at a monomeric level, PAR can modify PARP in a 
homogenous fashion. If the masking group can be removed photolytically, this method can 
be used to synthesize defined-length PAR in a controlled fashion. 
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Figure 2.1 illustrates the experiment’s general procedure. Traditional PAR modification 
experiments are carried out by feeding PARP with β-NAD+, which proceeds to heterogeneously 
modify PARP. Digestion of the PAR-PARP complex with hydroxylamine will cleave PAR off 
PARP’s modification sites to yield a polydisperse mixture of PAR. In our experiment, a modified 
β-NAD+ derivative will be used as feedstock instead in order to homogenously and 
monomerically modify PARP. The 2’-hydroxyl group of the β-NAD+ derivative will be masked 
by either a photocleavable masking group or a proparagyl group to prevent further modification. 
If the masking group is photocleavable, then in a stepwise fashion it can be removed to allow 
homogenous modification with the same masked β-NAD+ substrate. This can be used to produce 
defined-length PAR in a controlled fashion. 
The masking group of choice was the o-nitrobenzyl group. Removal of the masking 
group can be carried out by irradiation of long-wave uv light (~ 300 nm) under conditions that do 
not damage the substrate.
4
 For the irremovable masking group, the proparagyl group was chosen 
to use the enzymatically produced PAR in fluorophore experiments. Ideally the photocleavable 
β-NAD+ substrate would be fed into PARP first to form the backbone of PAR, then, after several 
iterations of this procedure, the proparagylated β-NAD+ substrate can be fed as the last block to 
cap PARylation at a desired length. Hydroxylamine cleavage would yield a proparagylated PAR 
of uniform length to be used in fluorophore experiments. 
Figure 2.2 shows target molecules of this project as well as the original β-NAD+ (2.1) for 
structural comparison, and scheme 2.1 illustrates the retrosynthetic analysis of each target 
molecule. Both target molecules 2.2 and 2.3 can be synthesized from their respective masked 
AMP (2.4 and 2.5) and nicotinamide mononucleotide (2.7). Both masked AMPs 2.4 and 2.5 can 
be synthesized through masking group coupling followed by phosphorylation of adenosine (2.6), 
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and phosphate 2.7 can be synthesized from tetraacetyl ribose (2.8). Both starting materials are 
commercially available in large quantities for cheap prices.  
 
  
Figure 2.2. Structures of β-NAD+, 2’-(o-nitrobenzyl)-β-NAD+, and 2’-proparagyl-β-
NAD
+
. Based on the structure of β-NAD+ (2.1), photocleavable masking groups such as o-
nitrobenzyl groups or fluorophore-coupling handles such as proparagyl groups will be used to 
mask the 2’-hydroxyl group to produce 2’-(o-nitrobenzyl)-β-NAD+ (2.2) and 2’-proparagyl-
β-NAD+ (2.3), respectively. 
Scheme 2.1. Retrosynthetic analysis of masked-β-NAD+. The molecule can be synthesized 
from a pyrophosphate coupling of masked AMP (2.4 or 2.5) and nicotinamide 
mononucleotide (2.6). Each of these molecules can be synthesized from commercially 
available sources of adenosine (2.6) and tetraacetyl ribose (2.8). 
16 
 
2.1.1. Building block synthesis 
Scheme 2.2 outlines the general progress of the experiment. The initial benzylation to 
produce 2.9 and proparagylation to form 2.11 were carried out using a modified procedure 
adopted by Chaulk and co-workers.
4
 Both the protection reaction and the phosphorylation were 
carried out successfully, and, following the phosphorylation, each phosphate was purified via C-
18 chromatography. For the pyrophosphate coupling step, the imidazolide activating group was 
chosen due to its simple synthesis and wide usage in pyrophosphate coupling. Both 2.10 and 2.12 
were synthesized in moderate quantities with synthetically useful overall yields (Scheme 2.2.A.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.2. Synthesis of building blocks 2.7, 2.10, and 2.12. A) Synthesis of AMP-
derivative building blocks 2.10 and 2.12. B) Synthesis of nicotinamide mononucleotide (2.7). 
C) Abbreviations of protecting groups used. 
A) 
B) 
C) 
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On the other hand, the synthesis of phosphate 2.7 was challenging (scheme 2.2.B.). 
Protocols used for the synthesis of 2.7 were adopted from procedures used by Tanimori and co-
workers and Kaminishi.
5,6
 Following the glycosylation of tetraacetate 2.8 with niacinamide to 
produce triacetate 2.13, quenching the reaction with methanol as performed by Tanimori and co-
workers resulted in large amounts of impurities in the product as well as extensive 
decomposition if the product was left in solution for too long. Hence, the product 2.13 was 
purified via C-18 chromatography without quenching the reaction. Initially the deprotection of 
the triacetate protecting groups was done by ammonia in methanol at 0
o
C; however, this resulted 
in a mixture of partially deprotected products and desired product 2.14. To ensure full 
deprotection of triacetate 2.13, sodium methoxide, a stronger base, was used at -20
o
C. The new 
condition resulted in full deprotection of 2.13 as desired and produced 2.14 in quantitative yields. 
The phosphorylation of 2.14 was done with phosphorous V oxychloride as usually done 
on nucleosides and nucleotides; however, its purification proved to be finicky and demanding, as 
it required multiple ion exchange columns and a large volume of water. There were few reports 
available in the literature with regards to alternate purification methods. The pure product was 
available only after running a C-18 column, followed by anion exchange columns in bicarbonate 
form and formate form, then a cation exchange column in proton form.  
 In the synthesis of pyrophosphate-based compounds, the pyrophosphate coupling step is 
of utmost importance as it is usually the final step to the synthesis, yet it is one of the most 
demanding reactions as it is required to be carried out in water-free conditions with polar 
solvents. Even a small amount of water can significantly lower the yield of the compound as the 
activated AMP-imidazolide would be hydrolyzed to produce AMP, which cannot couple with 
phosphate 2.7 without the activating group. To ensure that the solvent was kept dry, for the 
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pyrophosphate coupling of 2.10 and 2.12 with 2.7, a small amount of magnesium sulfate was 
added to the reaction along with manganese II chloride, the lewis acid catalyst for the coupling 
(Scheme 2.3). Both pyrophosphates 2.2 and 2.3 were produced in moderate yields and purified 
via preparatory HPLC.  
 
 
 
 
 
 
 
 
 
 
 
2.1.2. Automodification experiment with hTNKS-1  
 PARP-5, otherwise known as Tankyrase-1 (TNKS-1) is one of the enzymes that 
constitutes the PARP family, a group of enzymes that are automodified by PAR. To see if the 
modified β-NAD+ can homogenously modify PARP, we used human TNKS-1 in an in vitro 
automodification experiment with compound 2.3. In a previous work, Tan and co-workers have 
reported that the catalytic domain of hTNKS-1 is capable of automodification to produce PAR.
7
 
To this end, we were able to obtain the catalytic domain of hTNKS-1 for this experiment.  
 
Scheme 2.3. Pyrophosphate coupling of 2.10 and 2.12. The coupling was carried out with 
anhydrous manganese II chloride in dry formamide. Magnesium sulfate was added as a 
dehydrating agent. 
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Figure 2.3 Protein assays of human Tankyrase-1 (hTNKS-1) carried out with β-NAD+ and 
proparagyl-β-NAD+ (2.3) carried out for 90 minutes. The hTNKS-1 used did not show signs of 
automodification taking place. Experiment was carried out in 100 mM Tris-buffer with 10 mM 
MgCl2, 1 μM hTNKS-1, and 100 μM substrate. (From left to right) lane 1: Ladder, lane 2: 
hTNKS-1 + H2O, lane 3: hTNKS-1 + β-NAD
+
, lane 4: hTNKS-1 + β-NAD+ + 2.3, lane 5: 
hTNKS-1 + 2.3. 
 
The automodification experiment was carried out with hTNKS-1, unmodified β-NAD+, 
and proparagyl-β-NAD+ (2.3). Samples of β-NAD+ derivative 2.3 were obtained from Michael 
Lambrecht, and hTNKS-1 was incubated with β-NAD+ or 2.3 for 90 minutes and its results were 
visualized via Coomassie blue stain (Figure 2.3). Unfortunately, the hTNKS-1 catalytic domain 
samples used did not show signs of automodification: In figure 2, lanes 2 and 3 showed the 
hTNKS-1 bands moving the same distance down the gel, showing that automodification may not 
have taken place. Overnight incubation also failed to show visual evidence that automodification 
took place. Despite the lack of visual evidence that automodification took place, we cannot 
confirm that the catalytic domain of hTNKS-1 does not produce PAR through automodification. 
Since PARP processes automodification upon detection of DNA damage, it is likely that a 
sample of damaged DNA may need to be fed into the incubation mixture to trigger the 
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automodification process. It is also likely that the catalytic domain of hTNKS-1 itself is 
incapable of automodification and the full length hTNKS-1 may need to be used. 
 
2.2. Summary and outlook 
To investigate for means to homogenously modify PARP and produce defined length 
PAR, masked β-NAD+ derivatives 2.2 and 2.3 were successfully synthesized and purified. 
Compound 2.3 was used in an automodification experiment with hTNKS-1 to verify its ability to 
homogenously modify PARP. However, the results were inconclusive – the sample of hTNKS-1 
failed to carry out automodification even with the standard β-NAD+ substrate that was used, 
suggesting that either the full-length hTNKS-1 needs to be used or a sample of damaged DNA 
needs to be co-injected to initiate the modification procedure. 
Should this method succeed, one barrier still needs to be overcome. As shown in the 
previous chapter, automodification of PARP by PAR may result in branching for long-chain 
PAR. The masked β-NAD+ derivative used in this experiment only has the 2’-hydroxyl group of 
adenosine masked. Since branching tends to occur on the 2-hydroxyl group of ribose, there may 
arise the need to bioorthogonally mask the 2-hydroxyl group should we attempt to synthesize 
longer PAR molecules (>10 ADP units). A possible course of action would be to use masking 
groups that are cleaved under different wavelengths of light to orthogonally protect the two 
hydroxyl groups in question. 
Additionally, β-NAD+ derivative 2.3 could be used in the conclusive identification of 
number of PARP modification sites as well as their chemical nature. Methods utilized by Guy 
Poirier and Leung and their respective co-workers appear to be inconclusive, as there is little to 
no agreement in their final results of PARP modification sites.
8-10
 Although current reviews 
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generally agree that the modification occurs on glutamate, aspartate, and lysine residues, the lack 
of agreement among these studies necessitate the development of a method to conclusively 
identify the total number of and chemical nature of modification sites on PARP. If β-NAD+ 
derivative 2.3 is used in an automodification experiment with hPARP-1 then analyzed via 
LC/MS, at least the number of modification sites can be identified via the mass difference 
between the homogenously modified PARP and unmodified PARP. 
 
2.3. Materials and methods 
 
2.3.1. Chemical information 
General All reactions were run in flame or oven dried glassware under an atmosphere of 
dry nitrogen unless otherwise noted. Carbohydrates 8 and 13 were purchased from Carbosynth. 
Adenosine (6), and TBSCl were purchased from Chem Impex Intl. TMSOTf was purchased from 
TCI chemicals. N,N-diisopropylphosphoramidite was purchased from Alfa Aesar. All other 
reagents and starting materials were purchased from Sigma-Aldrich. Acetonitrile and DMF used 
in reactions were obtained from a solvent dispensing system. Diethyl ether was distilled from 
sodium metal. 4 Å molecular sieves were dried at 200
o
C on high vacuum overnight. Pyridine 
was distilled from CaH2 and stored on 4 Å molecular sieves. All other reagents were of standard 
commercial purity and were used as received.  
Compound Analysis  Analytical thin-layer chromatography was performed on EMD 
Merck silica gel plates with F254 indicator. Plates were visualized with UV light (254 nm) or 
staining with panisaldehyde. Silica gel for column chromatography was purchased from Sorbent 
Technologies (40-75 µm particle size). All 
1
H, 
13
C, and 
31
P NMR spectra were recorded at 500, 
125, and 202 MHz, respectively unless otherwise indicated. 
1
H and 
13
C NMR spectra were 
referenced to the residual solvent peak as reported by Fulmer et al
16
. 
 
Chemical shifts are 
reported in ppm and multiplicities are reported as s (singlet), d (doublet), t (triplet), q (quartet), p 
(pentet), h (hextet), hep (heptet), m (multiplet), and br (broad). Mass spectrometry analysis was 
performed by the University of Illinois Mass Spectrometry Center or by direct injection on an 
Agilent 6230 LC/MS TOF for samples run in negative ion mode. The LC/MS assay was 
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performed on the Agilent 6230 LC/MS TOF system with a 1.8 µm, 2.1x50 mm Agilent 
ZORBAX Eclipse Plus C18 column. Analytical HPLC analysis was performed on a Waters 
e2695 separations module with a Waters 2489 UV detector using a 5 µm, 4.6x150 mm Waters 
XBridge BEH130 HPLC column. All other C18 chromatography was performed using a 
Teledyne Isco CombiFlash Rf system with CombiFlash Gold columns.  
 
 
Compound 2.2: Imidazolide 2.10 (20 mg, 38 μmol, 1.2 eq) was dissolved in dry formamide (0.3 
mL) under a steady flow of dry N2 gas, followed by addition of phosphate 2.7 (10 mg, 31 μmol, 
1.0 eq), anhydrous manganese (II) chloride (6 mg, 47 μmol, 1.5 eq), and magnesium sulfate (7.5 
mg, 63 μmol, 2.0 eq). The mixture was left to stir at room temperature overnight. The reaction 
was purified via prep-HPLC to yield pyrophosphate 2.2 as a yellowish-white solid (6 mg, 25%). 
 
1
H NMR (500 MHz, D2O) δ 9.29 (s, 1H), 9.11 (d, J = 5.9 Hz, 1H), 8.79 (d, J = 7.8 Hz, 1H), 8.20 
– 8.12 (m, 1H), 8.02 (s, 1H),  7.60 (d, J = 8.1 Hz, 1H), 7.40 – 7.22 (m, 4H), 6.04 (d, J = 5.0 Hz, 
1H), 5.85 (d, J = 7.3 Hz, 1H), 5.23 (d, J = 13.8 Hz, 1H), 4.64 (d, J = 13.3 Hz, 1H), 3.55 – 3.48 (m, 
2H), 3.30 (t, J = 5.8 Hz, 1H), 3.10 – 3.02 (m, 1H), 2.62 – 2.58 (m, 1H). 
 
13
C NMR (125 MHz, D2O) δ 210.84, 185.82, 168.34, 161.96, 155.41, 152.84, 151.87, 129.56, 
128.79, 124.65, 105.78, 100.24, 85.16, 79.61, 77.73, 69.81, 46.85, 8.40. 
 
HRMS (ESI) m/z calc’d for C28H33N8O16P2 ([M+H]
+
) 799.1490, found 799.1478. 
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Compound 2.3: Imidazolide 2.12 (20 mg, 46 μmol, 1.2 eq) was dissolved in dry formamide (0.4 
mL) under a steady flow of dry N2 gas, followed by addition of phosphate 2.7 (12.5 mg, 38 μmol, 
1.0 eq), anhydrous manganese (II) chloride (7.2 mg, 57 μmol, 1.5 eq), and magnesium sulfate 
(9.2 mg, 77 μmol, 2.0 eq). The mixture was left to stir at room temperature overnight. The 
reaction was purified via prep-HPLC to yield pyrophosphate 2.3 as a yellowish-white solid (10 
mg, 34%). 
 
HRMS (ESI) m/z calc’d for C24H30N7O14P2 ([M+H]
+
) 335.0644, found 702.1323. 
 
 
Compound 2.4: Diol 2.9 (500 mg, 1.24 mmol, 1.0 eq) was dissolved in trimethyl phosphate (3.2 
mL) and cooled to 0
o
C in an ice bath. Phosphorous oxychloride (0.46 mL, 4.97 mmol, 4.0 eq) 
was added dropwise to the solution under a steady flow of dry N2 gas. The reaction mixture was 
stirred for 2 hours at 0
o
C. The reaction was monitored every 40 minutes via LCMS. The reaction 
was quenched with deionized water, concentrated via rotary evaporation, and purified via C-18 
chromatography to yield phosphate 2.4 as a white solid (277 mg, 46%). 
 
1
H NMR (500 MHz, DMSO-d6) δ 8.31 (s, 1H), 8.12 (s, 1H), 7.99 (dd, J = 8.1, 1.3 Hz, 1H), 
7.68 (d, J = 7.9 Hz, 1H), 7.62 (dd, J = 7.6, 7.5 Hz, 1H), 7.50 (dd, J = 8.0, 7.1 Hz, 1H), 7.33 (s, 
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2H), 6.15 (d, J = 5.4 Hz, 1H), 5.05 (d, J = 14.7 Hz, 1H), 4.91 (d, J = 14.7 Hz, 1H), 4.61 (dd, J = 
5.2, 5.2 Hz, 1H), 4.44 (dd, J = (4.5, 4.5 Hz, 1H), 4.18 – 4.14 (m, 1H), 4.14 – 4.08 (m, 1H), 4.02 – 
3.96 (m, 1H). 
 
13
C NMR (125 MHz, DMSO-d6) δ 208.4, 162.5, 159.7, 156.5, 153.1, 150.0, 139.9, 134.4, 129.3, 
129.2, 125.1, 94.1, 86.3, 81.7, 69.6, 68.7, 28.1. 
 
31
P NMR (202 MHz, CDCl3) δ 0.01. 
 
HRMS (ESI) m/z calc’d for C17H20N6O9P ([M+2H]
+
) 483.1029, found 483.1032. 
 
 
Compound 2.5: Diol 2.11 (95 mg, 0.311 mmol, 1.0 eq) was dissolved in trimethyl phosphate 
(0.8 mL) and cooled to 0
o
C in an ice bath. Phosphorous oxychloride (0.11 mL, 1.24 mmol, 4.0 
eq) was added dropwise to the solution under a steady flow of dry N2 gas. The reaction mixture 
was stirred for 2 hours at 0
o
C. The reaction was quenched with deionized water, concentrated via 
rotary evaporation, and purified via C-18 chromatography to yield phosphate 2.5 as a pale yellow 
solid (140 mg, quant.). 
 
1
H NMR (500 MHz, DMSO-d6) δ 8.51 (s, 1H), 8.33 (s, 1H), 6.18 (d, J = 5.4 Hz, 1H), 4.55 (dd, 
J = 5.0, 3.8 Hz, 1H), 4.30 – 4.26 (m, 1H), 4.23 (dd, J = 6.6, 2.4 Hz, 1H), 4.12 – 4.01 (m, 2H), 
3.47 (d, J = 10.7, 2H), 2.61 (t, J = 2.5 Hz, 1H). 
 
HRMS (ESI) m/z calc’d for C13H15N5O7P ([M]
-
) 384.0709, found 384.0711. 
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Compound 2.7: Phosphorylation of ribosyl nicotinamide (2.14) was carried out based on a 
procedure reported by Kaminishi et al.
3
 Triol 2.14 (1.4 g, 3.50 mmol, 1.0 eq) was dissolved in 
trimethyl phosphate (9.5 mL) in an ice bath, followed by addition of phosphorous oxychloride 
(1.35 mL, 14.7 mmol, 4.0 eq). The mixture was left to stir at 5
o
C overnight. The reaction was 
quenched by addition of cold aqueous solution of 2N sodium hydroxide (5 mL). The reaction 
mixture was washed with cold 1:3 mixture of acetonitrile and diethyl ether, and the aqueous 
layer was subjected to an ion exchange column (Dowex 1x2 100-200 mesh, formate form, 1.5 
cm x 12 cm) and eluted with water. The fractions corresponding to the product were pooled 
together and concentrated via rotary evaporation. The concentrated solution was purified once 
more via C-18 chromatography to yield phosphate 2.7 as a yellowish-white solid (200 mg, 17%). 
 
1
H NMR (500 MHz, D2O) δ 9.49 (s, 1H), 9.29 (d, J = 6.7 Hz, 1H), 8.99 (d, J = 8.2 Hz, 1H), 8.30 
(dd, J = 8.2, 6.1 Hz, 1H), 6.22 (d, J = 5.5 Hz, 1H), 4.64 (dd, J = 5.0, 2.3 Hz, 1H), 4.58 (dd, J = 
5.4, 2.3 Hz, 1H), 4.45 (ddd, J = 4.9, 2.4, 2.4 Hz, 1H), 4.30 (ddd, J = 12.0, 4.4, 2.3 Hz, 1H), 4.13 
(ddd, J = 12.0, 4.9, 2.3 Hz, 1H). 
 
13
C NMR (125 MHz, D2O) δ 210.9, 146.2, 142.7, 140.0, 134.3, 128.7, 100.2, 87.8, 77.9, 71.3, 
64.2, 44.0. 
 
HRMS (ESI) m/z calc’d for C11H16N2O8P ([M+H]
+
) 335.0644, found 335.0657. 
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Compound 2.9: A modified version of the procedure of Chaulk et al. was followed.
4
 Adenosine 
(2.6) (1.0 g, 3.74 mmol, 1.0 eq) was dissolved in hot DMF (30 mL) and heated to 60
o
C. Once the 
temperature was reached, the solution was cooled to 0
o
C in an ice bath. A suspension of sodium 
hydride (195 mg, 4.86 mmol, 1.3 eq) in cold DMF (3 mL) was added to the solution and stirred 
for 10 minutes in an ice bath, followed by the addition of a solution of o-nitrobenzyl bromide 
(1.213 g, 5.61 mmol, 1.5 eq) in cold DMF (3 mL) at room temperature. The reaction mixture was 
stirred for an additional 5 hours at room temperature. The mixture was poured out to a 250 mL 
round-bottom flask containing ice-cold water (30 mL) and stirred overnight. The precipitate from 
the reaction mixture was filtered out and washed with ethanol (3 x 20 mL). The solid obtained 
was dried in vacuum and characterized through 
1
H NMR, 
13
C NMR, and HSQC/HMBC to 
establish that the white precipitate was diol 2.9 (903 mg, 60%). 
 
1
H NMR (500 MHz, DMSO-d6) δ 8.35 (s, 1H), 8.09 (s, 1H), 7.97 (dd, J = 8.2, 1.2 Hz, 1H), 
7.62 (dd, J = 7.5, 1.8 Hz, 1H), 7.58 (ddd, J = 7.8, 7.0, 1.3 Hz, 1H), 7.49 (ddd, J = 8.4, 7.0, 1.8 Hz, 
1H), 7.36 (s, 2H), 6.10 (d, J = 6.1 Hz, 1H), 5.44 (d, J = 4.8 Hz, 1H), 5.43 (dd, J = 4.5, 4.4 Hz, 
1H), 5.03 (d, J = 14.7 Hz, 1H), 4.86 (d, J = 14.7 Hz, 1H), 4.59 (dd, J = 6.2, 4.7 Hz, 1H), 4.41 
(ddd, J = (4.9, 4.7, 3.4 Hz, 1H), 4.04 (ddd, J = (3.5, 3.4, 3.3 Hz, 1H), 3.69 (ddd, J = 12.2, 4.3, 4.1 
Hz, 1H), 3.58 (ddd, J = 12.2, 7.2, 3.6 Hz, 1H). 
 
13
C NMR (125 MHz, DMSO-d6) δ 159.7, 153.1, 152.1, 149.5, 140.3, 134.4, 129.6, 129.4, 125.0, 
92.6, 87.0, 86.6, 81.8, 77.4, 69.5, 68.6, 62.0. 
 
 
 
Compound 2.10: Phosphate 2.4 (24 mg, 49.9 μmol, 1.0 eq) was dissolved in DMSO (0.42 mL) 
under a steady flow of dry N2 gas at room temperature, followed by addition of aldrithiol (36 mg, 
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165 μmol, 3.3 eq), triphenylphosphine (43 mg, 165 μmol, 3.3 eq), and imidazole (54.3 mg, 798 
μmol, 16 eq). A stock solution of triethylamine (0.5 mL) was prepared in DMSO (2.5 mL), and 
0.1 mL of the stock solution was added to the reaction mixture under a steady flow of dry N2 gas 
at room temperature. The mixture was left to stir at room temperature for 5 hours. The product 
was purified via C-18 chromatography to yield imidazolide 2.10 as a yellow solid (20 mg, 77%). 
 
1
H NMR (500 MHz, CD3OD) δ 8.31 (s, 1H), 8.14 (s, 1H), 8.05 (s, 1H), 7.89 (dd, J = 8.2, 1.3 
Hz), 7.64 (dd, J = 7.8, 1.4 Hz, 1H), 7.51 (ddd, J = 7.6, 7.6, 1.3 Hz, 1H), 7.40 (ddd, J = 7.7, 7.4, 
1.5 Hz, 1H), 7.33 (s 1H), 7.25 (s, 2H), 7.06 (s, 1H), 6.16 (d, J = 5.9 Hz, 1H), 5.13 (d, J = 14.4 Hz, 
1H), 4.94 (d, J = 14.3 Hz, 1H), 4.62 (dd, J = 5.9, 4.8 Hz, 1H), 4.41 (dd, J = 5.0, 3.5 Hz, 1H), 4.21 
(dd, J = 3.6, 1.8 Hz, 1H), 4.10 (ddd, J = 11.4, 5.8, 3.5 Hz, 1H), 4.04 (ddd, J = 11.4, 6.2, 3.7 Hz, 
1H). 
 
Compound 2.11: A modified version of the procedure of Chaulk et al. was followed.
4
 
Adenosine (2.6) (1.0 g, 3.74 mmol, 1.0 eq) was dissolved in hot DMF (35 mL) and heated to 
60
o
C. Once the temperature was reached, the solution was cooled to 0
o
C in an ice bath. A 
suspension of sodium hydride (195 mg, 4.86 mmol, 1.3 eq) in cold DMF (5 mL) was added to 
the solution and stirred for 15 minutes in an ice bath, followed by the addition of a solution of 
proparagyl bromide (834.2 mg, 5.61 mmol, 1.5 eq) in cold DMF (3 mL) at room temperature. 
The reaction mixture was stirred for an additional 5 hours at room temperature. The mixture was 
quenched with MeOH (3 mL) and the solvent was removed under reduced pressure. The product 
was purified via silica column chromatography (Rf = 0.50 in 9:1 DCM:MeOH) and 
recrystallization from EtOH to yield compound 2.11 as pale yellow oil (381.5 mg, 31%). 
 
1
H NMR (500 MHz, DMSO-d6) δ 8.35 (s, 1H), 8.12 (s, 1H), 7.35 (s, 2H), 6.00 (d, J = 6.4 Hz, 
1H), 5.47 (dd, J = 7.1, 4.5 Hz, 1H), 5.34 (d, J = 5.1 Hz, 1H), 4.67 (dd, J = 6.4, 4.8 Hz, 1H), 4.36 
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– 4.31 (m, 2H), 4.25 (dd, J = 15.9, 2.4 Hz, 1H), 4.17 (dd, J = 15.9, 2.4 Hz, 1H), 3.98 (dd, J = 6.4, 
3.2 Hz, 1H), 3.65 (ddd, J = 12.1, 8.0, 4.0 Hz, 1H), 3.54 (ddd, J = 12.1, 7.1, 3.5 Hz, 1H). 
 
HRMS (ESI) m/z calc’d for C13H16N5O4 ([M+H]
+
) 306.1202, found 306.1193. 
 
 
Compound 2.12: Phosphate 2.5 (100 mg, 0.260 mmol, 1.0 eq) was dissolved in DMSO (2.6 mL) 
under a steady flow of dry N2 gas at room temperature, followed by addition of aldrithiol (189 
mg, 0.859 mmol, 3.3 eq), triphenylphosphine (225 mg, 0.859 mmol, 3.3 eq), imidazole (283 mg, 
4.16 mmol, 16 eq) and triethylamine (91 μL). The mixture was left to stir at room temperature 
for 5 hours. The product was purified via C-18 chromatography to yield imidazolide 2.12 as a 
yellow solid (25.5 mg, 22%). 
 
1
H NMR (500 MHz, CD3OD) δ 8.40 (s, 1H), 8.19 (s, 1H), 8.04 (s, 1H), 8.01 (s, 1H), 7.05 (s, 
1H), 6.13 (d, J = 5.8 Hz, 1H), 4.73 (t, J = 5.5 Hz, 1H), 4.41 – 4.36 (m, 1H), 4.30 (dd, J = 8.4, 2.4 
Hz, 2H), 4.17 – 4.14 (m, 1H) 4.11 – 3.99 (m, 2H), 2.76 (t, J = 2.4 Hz, 1H). 
 
31
P NMR (202 MHz, D2O) δ -6.96 
 
HRMS (ESI) m/z calc’d for C16H19N7O6P ([M+H]
+
) 436.1134, found 436.1138. 
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Compound 2.13: Tetraacetate 2.8 (2.0 g, 6.28 mmol, 1.0 eq) was dissolved in dry acetonitrile 
(20 mL) under a steady flow of dry N2 gas at room temperature, followed by addition of 
niacinamide (920 mg, 7.54 mmol, 1.2 eq). Trimethylsilyl triflate (1.35 mL, 7.54 mmol, 1.2 eq) 
was added dropwise to the reaction mixture under a steady flow of dry N2 gas at room 
temperature. The mixture was left to stir at room temperature for 2 hours. The product was 
purified via C-18 chromatography to yield triacetate 2.13 as a white foamy solid (2.91 g, 87%). 
 
1
H NMR (500 MHz, D2O) δ 9.51 (dd, J = 1.7, 1.6 Hz, 1H), 9.27 (dd, J = 5.1, 1.7 Hz, 1H), 9.05 
(dd, J = 5.1, 1.4 Hz, 1H), 8.34 (dd, J = 6.9, 7.4 Hz, 1H), 6.65 (d, J = 3.8 Hz, 1H), 5.63 (dd, J = 
5.4, 3.8 Hz, 1H), 5.52 (dd, J = 5.4, 5.4 Hz, 1H), 4.96 (ddd, J = 5.4, 2.7, 2.7 Hz, 1H), 4.60 (dd, J = 
13.2, 2.8 Hz, 2H), 2.23 (s, 3H), 2.19 (s, 3H), 2.16 (s, 3H). 
13
C NMR (125 MHz, D2O) δ 210.5, 198.6, 195.1, 172.6, 146.4, 143.3, 140.6, 128.8, 97.5, 82.8, 
76.6, 69.6, 62.8, 44.0, 31.4, 20.4, 20.0. 
 
HRMS (ESI) m/z calc’d for C17H21N2O8 ([M]
+
) 381.1298, found 381.1305. 
 
 
Compound 2.14: Triacetate 2.13 (2.9 g, 5.47 mmol, 1.0 eq) was dissolved in methanol (50 mL) 
in an ice bath, followed by addition of a solution of sodium methoxide (1.477 g, 27.3 mmol, 5.0 
eq) dissolved in ice-cold methanol (50 mL). The mixture was left to stir at -20
o
C overnight. The 
reaction was quenched by addition of glacial acetic acid (2 mL) and the product was purified via 
C-18 chromatography to yield triol 2.14 as a white foamy solid (2.70 g, quant.). 
 
1
H NMR (500 MHz, D2O) δ 9.62 (dd, J = 1.5, 1.3 Hz, 1H), 9.28 (ddd, J = 6.5, 1.3, 1.3 Hz, 1H), 
8.99 (dd, J = 8.0, 1.5, 1.3 Hz, 1H), 8.29 (dd, J = 8.1, 6.3 Hz, 1H), 6.26 (d, J = 4.4 Hz, 1H), 4.52 (t, 
J = 4.7 Hz, 1H), 4.50 (ddd, J = 3.5, 3.5, 2.9 Hz, 1H), 4.37 (dd, J = 4.6, 4.6 Hz, 1H), 4.06 (dd, J = 
12.9, 2.9 Hz, 1H), 3.91 (dd, J = 12.9, 3.6 Hz, 1H). 
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13
C NMR (125 MHz, D2O) δ 210.6, 145.8, 142.9, 140.6, 128.6, 100.1, 87.9, 77.6, 70.0, 60.4, 
44.0. 
 
HRMS (ESI) m/z calc’d for C11H15N2O5 ([M]
+
) 255.0981, found 255.0990. 
 
2.3.2. Biological experiment 
Human Tankyrase-1 (hTNKS-1) automodification experiment Concentrated TNKS-1 stock 
solutions were diluted to 1 μM. Next, to four 0.5 mL tubes were added 6 µL of PARP activity 
buffer (100 mM Tris, 10 mM MgCl2), 1 µL of 1 mM TCEP, and 2 µL of the diluted hTNKS-1. 
The following treatments were implemented to each tube: Tube 1: 1 µL of deionized water; tube 
2: 1 µL of a 100 µM solution of β-NAD+; tube 3: 1 µL of a 1:1 mixture of the prepared 100 µM 
β-NAD+ solution and the 100 µM solution of 2.3; tube 4: 1 µL of a 100 µM solution of 2.3. The 
tubes were incubated at room temperature for 90 minutes then analyzed via SDS-PAGE on a 
4~20% gel. The gel was stained by Coomassie Blue and the results visualized by BIO-RAD 
Molecular Imager Gel-Doc
TM
 XR+. This process was repeated a second time with a longer 
incubation time (17 hr). 
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2.3.3. Spectra 
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CHAPTER 3 
INVESTIGATION OF CELL-PERMEABLE PARG INHIBITORS 
 Along with PARP inhibition, PARG inhibition has been suggested as a plausible means 
to induce cell death via PARthanatos;
1,2
 however, investigation of PARG inhibitors is stymied by 
the lack of cell-permeable and specific PARG inhibitors. ADP-HPD, the most potent and 
specific PARG inhibitor known in literature,
3
 lacks the lipophilicity to penetrate cell membranes. 
Jacobson and co-workers previously used an alkylated derivative of ADP-HPD in the 
investigation of the SAR of ADP-HPD; however, cell-permeability assays were not carried out 
on the molecule.
4
  
 Here we report the strategy of employing hydrophobic masking groups to the 
pyrophosphate moiety of ADP-HPM to examine its cell-permeability while maintaining potent 
inhibition of PARG. The pyrophosphate is coupled to a lipophilic alanine ester to enhance cell 
penetration. Once the molecule enters the cytosol, the alanine ester is enzymatically removed to 
expose the deprotected ADP-HPD. 
 
3.1. Masking group strategies 
Masking group strategies have been extensively employed in the literature for 
investigations of phosphate, diphosphate, triphosphate, and pyrophosphate drugs.
5-8
 Among the 
masking groups, amino-acid-based masking groups have garnered considerable interest due to 
their relative stability to other masking groups and nontoxic byproduct of amino acids.
9
 It is 
utilized for commercially approved prodrugs such as Sovaldi.
10
 The lipophilicity of the prodrug 
can be tuned by changing the ester of the amino acid. 
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 Scheme 3.1 shows the mechanism of activation of phosphoramidate prodrugs. The amino 
acid ester’s lipid is cleaved by esterase, leading to a spontaneous loss of the neighboring masking 
group – phenol in the case of aryl phosphoramidates (Scheme 3.1A) and one of the two amino 
acids in the case of diamides (Scheme 3.1B). The remaining amino acid subsequently cyclizes 
into the phosphate to form a heteroatomic pentacyclic intermediate, which is hydrolyzed. Finally, 
the enzyme HINT1 enzymatically removes the remaining amino acid to reveal the deprotected 
phosphate. 
 While most of the reported masking groups are utilized in phosphate or diphosphate 
prodrugs, pyrophosphate masking groups have emerged in the recent years. In particular, Gray 
and co-workers have been able to utilize the amino-acid-based masking group strategy in their 
investigation of a K-Ras inhibitor (3.1).
8
 Based on the structure of the K-ras inhibitor and the 
original structure of ADP-HPM (3.2) shown in figure 3.1, here we propose an amino-acid-ester-
masked ADP-HPM (3.3) that can be used to examine the cell-permeability of the prodrug. A 
possible mechanism of activation of the pyrophosphate prodrug is shown in scheme 3.2. Similar 
to scheme 3.1, esterase should cleave the lipophilic ester moiety, followed by removal of the 
B) 
A) 
Scheme 3.1. Enzymatic cleavage of amino-acid-based masking groups on phosphate 
prodrugs.
9
 The enzymes esterase and HINT-1 are involved in the enzymatic removal of the 
amino-acid-ester masking groups. Shown here are the mechanisms of aryl phosphoramidate 
prodrug activation (A) and diamide prodrug activation (B). 
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amino acid by phosphoramidase HINT-1. To ensure the stability of the P—N bond of the 
phosphoramidate functional group, a stability assay will be carried out via LC/MS to monitor its 
cleavage over a period of time. 
  
3.2. Synthesis and evaluation of masked ADP-HPM 
3.2.1. Synthesis of protected phosphoramidate 3.5 
The retrosynthetic analysis is shown below in scheme 3.3. The pyrophosphate will be 
synthesized from commercially available AMP morpholide 3.4 and protected phosphoramidate 
Scheme 3.2. Possible mechanism of enzymatic cleavage of amino acid ester masking 
groups on pyrophosphate prodrugs. Similar to the removal of masking groups on aryl 
phosphoramidate or diamide prodrugs, the enzymes esterase and HINT-1 carry out a stepwise 
removal of the amino acid ester masking group to expose the deprotected pyrophosphate 
moiety. 
Figure 3.1. Structures of K-ras inhibitor SML-10-70-1, ADP-HPM, and masked-ADP-
HPM. Based on the structure of K-ras inhibitor SML-10-70-1 (3.1) developed by Gray and 
co-workers,
8
 a similar masking group will be utilized on the pyrophosphate moiety of ADP-
HPM (3.2) to produce masked-ADP-HPD (3.3) 
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3.5. The protected phosphoramidate will be synthesized from H-phosphonate 3.7 and L-alanine 
ester 3.6 following a modified procedure used by Gray and Zhao and their respective co-
workers.
8,10
 H-phosphonate 3.7 can be synthesized from alcohol 3.10 following procedures by 
Zhao and co-workers,
10
 and alcohol 3.10 can be produced from a series of protection and 
reduction reactions of commercially available proline derivative 3.11.  
 
 Scheme 3.4 shows the overall progress of the synthesis of 3.5. The benzyl-group-based 
protecting groups were chosen since removal of acid- or base-labile protecting groups in 
subsequent steps had possibilities of cleaving the P—N bond of the phosphoramidate. The 
protection of the secondary amine of l-trans-4-hydroxyproline methyl ester (3.11) was carried 
out with benzyl chloroformate and N,N-diisopropylethylamine in DCM. Benzylation of the 
hydroxyl group was carried out with benzyl bromide and sodium hydride in THF. 
Tetrabutylammonium iodide (TBAI) was added to enhance the rate of conversion.
11
 Finally, 
Scheme 3.3. Retrosynthetic analysis of masked-ADP-HPM. The molecule can be 
synthesized from a pyrophosphate coupling of a commercially available source of activated 
AMP morpholide 3.4 and protected phosphoramidate 3.5, which in turn can be synthesized 
from building blocks of alanine ester 3.6 and trans-L-4-hydroxyproline methyl ester (3.11). 
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reduction of the ester was carried out by lithium borohydride, a milder reducing agent than 
lithium aluminum hydride, which could react with the Cbz-protecting group, but stronger agent 
than sodium borohydride to provide a quantitative yield of alcohol 3.10. The formation of H-
phosphonate 3.7 was carried out following a modified procedure reported by Zhao and co-
workers.
10
 
A) 
B) 
C) 
D) 
Scheme 3.4. Synthesis of protected phosphoramidate 3.5. A) Synthesis of H-phosphonate 
building block 3.7. B) Synthesis of alanine ester 3.6. C) Synthesis of protected 
phosphoramidate 3.5. D) Abbreviations of protecting groups used. 
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 Following the synthesis of protected alanine ester 3.14 and its subsequent deprotection, 
synthesis of phosphoramidate 3.5 was carried out following the procedure utilized by Gray and 
co-workers.
8
 The synthesis began with a modified Atherton-Todd reaction also utilized by Zhao 
and co-workers,
10
 followed by deprotection of the fluorenylmethyl group with triethylamine in 
acetonitrile. While the two original papers use piperidine to remove the protecting group, 
triethylamine was utilized for this reaction under suspicion that the piperidinium salt may 
interfere with the subsequent pyrophosphate coupling step, discussed in section 3.2.3. 
 
 
 
Product peak 
m/z = 603 
30 min 
2 hr 
6 hr 
24 hr 
Figure 3.2. Monitoring of P—N bond stability on phosphoramidate 3,5. 1 mg samples of 
phosphoramidate 3.5 were dissolved in 20% CH3CN in deionized H2O (v/v) and monitored 
by LC/MS over a period of 24 hours. The phosphoramidate was detected at an m/z of 603 for 
up to 24 hours in solution, proving that the compound was stable to hydrolysis. 
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3.2.2. Masking group stability assay 
With phosphoramidate 3.5 in hand, we monitored its stability by LCMS. The 
phosphoramidate was dissolved in a solution of 20% acetonitrile in deionized water and mass 
spectra were taken at different time intervals. As shown in figure 3.2, the compound was 
detected in solution for up to 24 hours and longer, indicating that the P—N bond was stable in 
aqueous solution without undergoing hydrolysis. Furthermore, the overnight deprotection of the 
fluorenylmethyl group with triethylamine in acetonitrile following the Atherton-Todd coupling 
between the alanine ester and the H-phosphonate shows that the P—N bond can withstand mildly 
to moderately basic conditions for up to 24 hours.  
 
3.2.3. Completing the synthesis of masked ADP-HPM 
Much like the pyrophosphate coupling step as discussed in chapter 2, the pyrophosphate 
coupling step of masked ADP-HPM was the toughest step in the synthesis. Attempts to carry out 
the coupling are outlined in scheme 3.5. Initially the pyrophosphate reaction was carried out 
under conditions similar to that of Gray and co-workers,
8
 with 5-ethylthio-1H-tetrazole as the 
catalyst and piperidinium as the counter-ion. However, no reaction occurred under these 
conditions. When the pyrophosphate coupling was attempted with similar reaction conditions 
using MnCl2 in anhydrous formamide as used in chapter 2, a very low conversion rate was 
observed. In expectations that changing the lewis acid could result in a better conversion rate, 
conditions utilized by Vincent and co-workers, with MgCl2 in dry DMF, and conditions by 
Lambrecht and co-workers, with ZnCl2 in DMF, were employed.
12,13
 While both conditions 
resulted in slightly higher conversion rates than when MnCl2 was used, the conversion rate was 
still below 10%, which was not considered synthetically useful. 
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Under the assumption that the piperidinium counter-ion may have interfered with the 
pyrophosphate coupling, we synthesized phosphoramidate 3.5 without using piperidine to 
deprotect the fluorenylmethyl group on the phosphoramidate after the Atherton-Todd coupling. 
Then, using a commercially available AMP-morpholide (3.4) from Sigma-Aldrich, the 
pyrophosphate coupling was carried out as done by Gray and co-workers.
8
 This time the 
pyrophosphate coupling was a success, with a conversion rate of over 50%. The pyrophosphate 
was purifiable with C-18 chromatography.  
 
 
 
 
 
 
 
Counter-ion 
of 3.5 
Activating 
group 
Conditions Results 
Piperidinium 
ion 
Morpholine 5-ethylthio-1H-tetrazole in pyridine 
r.t., 3 hr
6
 
No reaction 
Et3NH
+
 Imidazole MnCl2, MgSO4, anhydrous formamide 
r.t., 18 hr 
<5% conversion 
Et3NH
+
 Imidazole MgCl2, anhydrous DMF 
r.t., 24 hr
10
 
<10% conversion 
Et3NH
+
 Imidazole ZnCl2, anhydrous DMF 
r.t., 72 hr
11
 
<10% conversion 
Et3NH
+
 Morpholine 5-ethylthio-1H-tetrazole in pyridine 
r.t., 16 hr
6
 
>50% conversion, 
54% yield 
 
Table 3.1. Pyrophosphate coupling conditions 
 
Scheme 3.5. Pyrophosphate coupling of 3.5. AG = Activating Group. Conditions of the 
coupling are outlined in table 3.1 
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The synthesis of 3.3 was finalized with hydrogenation to safely remove the benzyl and 
benzyloxycarbonyl groups. Conditions for the hydrogenation were adopted from a procedure 
used by Wanner and co-workers.
14
 After 3 days of stirring under constant positive pressure of 
gaseous hydrogen, protected pyrophosphate 3.15 was converted into pyrophosphate 3.3. Initially 
there was a minor setback where we obtained 2:2:1 ratio of starting material 3.15, partially 
deprotected product, and fully deprotected product (desired product) 3.3. The results weren’t too 
surprising since there are reports for similar substrates that the hydrogenolysis of the benzyl 
group proceeds more slowly than that of the benzyloxycarbonyl group.
15
 Different 
hydrogenolysis conditions need to be sought to ensure efficient removal of both protecting 
groups. 
 
3.2.4. Masking group cleavage assay with HINT-1 
 Even if masked ADP-HPM 3.3 were able to penetrate the cell membrane, if its masking 
group of alanine ester cannot be cleaved in the cell, it cannot achieve the desired effects as a 
PARG inhibitor. Histidine Triad Nucleotide-binding Protein 1 (HINT-1) is a phosphoramidase 
that has been reported to cleave amino acids from phosphates.
16,17
 To see if the masking group of 
modified ADP-HPM 3.3 can be cleaved by HINT-1, we used human HINT-1 in an in vitro 
cleavage assay with compound 3.3.  
Scheme 3.6. Hydrogenolysis of pyrophosphate 3.15. Conditions were adopted from the 
works of Wanner and co-workers.
14
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Figure 3.3. Monitoring of masking group cleavage by HINT-1. The assay was based off 
of a similar study carried out by Bieganowski and co-workers.
16
 While some amount of 
ADP-HPM was detected, the major species in the reaction solution were starting material 
(blue, m/z = 708) and AMP (red, m/z = 345). Not shown in the spectrum are traces of 
hydroxyproline phosphoramidate 3.16 (m/z = 379) due to lack of fluorescence. 
Pyrophosphate 3.3 AMP 
Scheme 3.7. Cleavage of the pyrophosphate by HINT-1. It is likely that the bulky alanine 
ester prevented HINT-1’s cleavage of the amino acid and instead AMP was cleaved from the 
pyrophosphate. 
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The experiment was based off a similar assay carried out by Bieganowski and co-
workers.
16
 The cleavage assay was carried out with hHint-1, masked ADP-HPM 3.3, both in a 
PIPES-based buffer. Varying amounts of hHINT-1 were incubated with 3.3 for 5 hours and their 
results were analyzed via LC/MS (Figure 3.3). While we were able to detect some amount of 
deprotected ADP-HPM in solution, it appeared that most of 3.3 were cleaved into AMP and 
hydroxyproline phosphoramidate 3.16 (Scheme 3.7), both of which were detected by LC/MS. 
The fluorescence peaks of 3.16 are not shown in figure 3.3 due to the molecule’s innate lack of 
chromophore functional groups. Given that HINT-1 has only been reported to cleave ammonia, 
short-chain amines, and amino acid from AMP, it is likely that the bulky group of the alanine 
ester of pyrophosphate 3.3 prevented HINT-1 from cleaving it successfully, and instead HINT-1 
cleaved AMP from the substrate. It is also likely that the long-chain ester group needs to be 
removed by an esterase to convert it into a suitable substrate for HINT-1. 
  
3.3. Summary and future directions 
 As an alternative to PARP inhibition for genotoxic chemotherapy, PARG inhibition has 
generated considerable interest in the field of chemical biology; however, the lack of cell-
permeable and potent PARG inhibitors stymies any further progress in this field. To overcome 
this barrier, we have proposed the design of masked derivatives of ADP-HPM with hydrophobic 
groups to enhance its cell permeability. To this end, we successfully synthesized the desired 
pyrophosphate 3.3 over 10 steps, highlighting the synthetic accessibility of the test molecule. In 
order to test its efficacy, enzymatic assays need to be carried out: First, we must investigate that 
the hydrophobic masking group can be removed reliably from the pyrophosphate moiety by 
carboxyesterase, an enzyme that can cleave esters from amino acids, and phosphoramidase 
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HINT-1. Once it is shown that the enzymes can remove the masking group, whole cell CETSA 
analysis can be carried out to measure the potency of the masked ADP-HPD. 
 
3.4. Materials and methods 
 
3.4.1. General chemical information 
General All reactions were run in flame or oven dried glassware under an atmosphere of 
dry nitrogen unless otherwise noted. 9-fluorenylmethanol (FmOH) was purchased from Chem 
Impex Intl. EDAC and 5-ethylthio-1-H-tetrazole were purchased from TCI chemicals. 
Hydrochloric acid was purchased from Fisher Scientific. Compressed hydrogen gas was 
purchased from Matheson Tri-Gas. All other reagents and starting materials were purchased 
from Sigma-Aldrich. Acetonitrile and THF used in reactions were obtained from a solvent 
dispensing system. Pyridine was stored on 4 Å molecular sieves that were dried quickly under 
high vacuum. All other reagents were of standard commercial purity and were used as received.  
Compound Analysis  Analytical thin-layer chromatography was performed on EMD 
Merck silica gel plates with F254 indicator. Plates were visualized with UV light (254 nm) or 
staining with p-anisaldehyde. Silica gel for column chromatography was purchased from Sorbent 
Technologies (40-75 µm particle size). All 
1
H, 
13
C, and 
31
P NMR spectra were recorded at 500, 
125, and 202 MHz, respectively unless otherwise indicated. 
1
H and 
13
C NMR spectra were 
referenced to the residual solvent peak as reported by Fulmer et al
16
. 
 
Chemical shifts are 
reported in ppm and multiplicities are reported as s (singlet), d (doublet), t (triplet), q (quartet), p 
(pentet), h (hextet), hep (heptet), m (multiplet), and br (broad). Mass spectrometry analysis was 
performed by the University of Illinois Mass Spectrometry Center. The LC/MS assay was 
performed on the Agilent 6230 LC/MS TOF system with a 1.8 µm, 2.1x50 mm Agilent 
ZORBAX Eclipse Plus C18 column. Analytical HPLC analysis was performed on a Waters 
e2695 separations module with a Waters 2489 UV detector using a 5 µm, 4.6x150 mm Waters 
XBridge BEH130 HPLC column. All other C18 chromatography was performed using a 
Teledyne Isco CombiFlash Rf system with CombiFlash Gold columns.  
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Abbreviations used 
 
 
 
Compound 3.3: Protected pyrophosphate 3.15 (25 mg, 26.8 μmol, 1 eq) was dissolved in 
methanol (0.32 mL), followed by the addition of concentrated HCl (2.5 μL, 30.3 μmol, 1.13 eq). 
10% palladium on carbon (5 mg) was added to the solution and left to stir under positive 
pressure of hydrogen gas at room temperature for 3 days. The solid was filtered and the solvent 
was removed via rotary evaporation and the product was purified via preparatory HPLC to yield 
pyrophosphate 3.3 as clear oil (1 mg, 5 %). 
 
31
P NMR (202 MHz, D2O) δ -0.82, -1.04, -10.54. 
 
HRMS (ESI) m/z calc’d for C26H46N7O12P2 ([M]
-
) 710.2680, found 710.2664. 
 
Compound 3.5: Compound 115 was synthesized via a modified procedure used by Gray and co-
workers
6
. Specifically, triethylamine (0.93 mL, 6.67 mmol, 6.0 eq) and carbon tetrachloride (1.7 
mL) was added into a solution of alanine ester 3.6 (268 mg, 1.33 mmol, 1.2 eq) in anhydrous 
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THF (16.8 mL) at 0
o
C. A solution of H-phosphonate 3.7 (645 mg, 1.11 mmol, 1.0 eq) dissolved 
in a solution of anhydrous THF (6.4 mL) was added to the reaction mixture at 0
o
C and gradually 
warmed up to room temperature. The reaction mixture was left to stir at room temperature for 3 
hours. The solvent was removed via rotary evaporation and the resulting slurry was redissolved 
in DCM (50 mL), washed with 0.1 M HCl (3 x 30 mL), and dried over Na2SO4. The solvent was 
removed via rotary evaporation and the resultant slurry was redissolved in a 1:2 mixture of 
triethylamine:acetonitrile (33 mL). The mixture was left to stir at room temperature for 17 hours. 
After removal of the solvent via rotary evaporation, the product was purified via silica column 
chromatography (Rf = 0.18 in 9:1 DCM:Methanol) to yield compound 3.5 as yellow oil (182 mg, 
27%). 
 
1
H NMR (500 MHz, CD3CN) δ 7.40 – 7.25 (m, 10H), 5.15 – 5.00 (m, 2H), 4.57 – 4.38 (m, 2H), 
4.20 – 4.10 (m, 1H), 4.07 – 3.85 (m, 3H), 3.84 – 3.55 (m, 3H), 3.43 – 3.33 (m, 1H), 2.16 – 2.07 
(m, 2H), 1.70 – 1.60 (m, 1H), 1.34 – 1.22 (m, 8H), 0.91 – 0.84 (m, 6H). 
  
13
C NMR (125 MHz, CD3CN) δ 176.50, 155.92, 139.65, 138.21, 129.42, 129.27, 128.79, 
128.62, 128.56, 128.43, 78.00, 71.55, 69.18, 68.11, 67.37, 53.26, 51.49, 46.35, 37.69, 34.78, 
34.15, 20.51, 17.70, 14.72.  
 
31
P NMR (202 MHz, CD3CN) δ 5.00.  
 
HRMS (ESI) m/z calc’d C31H46N2O8P ([M+H]
+
) 605.2992, found 605.2991. 
 
Compound 3.6: Boc-protected L-alanine ester 3.14 (500. mg, 1.66 mmol, 1.0 eq) was dissolved 
in ethyl acetate (3 mL), followed by addition of 4 M dioxane solution of HCl (2.9 mL, 11.6 
mmol, 7.0 eq). The reaction mixture was left to stir at room temperature for 2 hours, and then the 
solvents were removed via rotary evaporation. The product was used in subsequent steps without 
further purification. 
56 
 
HRMS (ESI) m/z calc’d for C11H24NO2 ([M+H]
+
) 202.1807, found 202.1809. 
 
 
Compound 3.7: Compound 109 was synthesized via a modified procedure used by Zhao and co-
workers
8
. Specifically, A solution of 9-fluorenemethanol (759 mg, 3.87 mmol, 1.1 eq) dissolved 
in anhydrous pyridine (10 mL) was added into a solution of diphenyl phosphite (0.88 mL, 4.57 
mmol, 1.3 eq) in anhydrous pyridine (10 mL) and stirred at 0
o
C for 30 minutes. A solution of 
alcohol 3.10 (1.20 g, 3.52 mmol, 1.0 eq) dissolved in anhydrous pyridine (7 mL) was added to 
the reaction mixture at 0
o
C and heated up to 45
o
C. The reaction mixture was left to stir at 45
o
C 
for 1 hour. The solvent was removed via rotary evaporation and the product was purified via 
silica column chromatography (Rf = 0.31 in 1:1 ethyl acetate:hexanes) to yield compound 3.7 as 
yellow oil (1.34 g, 67%). 
 
1
H NMR (500 MHz, CDCl3) δ 9.51 (dd, J = 1.7, 1.6 Hz, 1H, H-6), 9.27 (dd, J = 5.1, 1.7 Hz, 1H, 
H-9), 9.05 (dd, J = 5.1, 1.4 Hz, 1H, H-7), 8.34 (dd, J = 6.9, 7.4 Hz, 1H, H-8), 6.65 (d, J = 3.8 Hz, 
1H, H-1), 5.63 (dd, J = 5.4, 3.8 Hz, 1H, H-2), 5.52 (dd, J = 5.4, 5.4 Hz, 1H, H-3), 4.96 (ddd, J = 
5.4, 2.7, 2.7 Hz, 1H, H-4), 4.60 (dd, J = 13.2, 2.8 Hz, 2H, H-5), 2.23 (s, 3H, Ac-12), 2.19 (s, 3H, 
Ac-11), 2.16 (s, 3H, Ac-10). 
13
C NMR (125 MHz, CDCl3) δ 141.66, 128.76, 128.31, 128.27, 128.24, 128.08, 127.89, 127.83, 
127.56, 127.54, 127.51, 127.48, 127.45, 125.29, 120.37, 71.28, 67.61, 67.32, 67.21, 56.49, 52.49, 
48.40, 48.35, 34.02. 
 
31
P NMR (202 MHz, CDCl3) δ 5.43. 
 
HRMS (ESI) m/z calc’d for C34H35NO6P ([M+H]
+
) 584.2202, found 584.2202. 
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Compound 3.10: Ester 3.13 (8.28 g, 21.3 mmol, 1.0 eq) was dissolved in dry THF (185 mL) in 
an ice bath, followed by addition of Lithium borohydride (1.5 g, 71.0 mmol, 3.3 eq) at 0
o
C. The 
solution was left to stir for 30 minutes. The reaction was allowed to warm up to room 
temperature and stirred for additional 2 hours. The reaction was quenched by addition of 1 M 
HCl until the quenching did not produce additional gas, and the reaction mixture was diluted 
with deionized water (30 mL). The aqueous solution was extracted with ethyl acetate (3 x 200 
mL), and the combined organic fractions were washed with water (200 mL) and brine (200 mL). 
The organic fraction was dried over Na2SO4 and concentrated via rotary evaporation. The 
product was purified via silica column chromatography (Rf = 0.37 in 1:1 ethyl acetate:hexanes) 
to yield compound 3.10 as clear oil (6.57 mg, quant.). 
 
1
H NMR (500 MHz, CDCl3) δ 7.38 – 7.27 (m, 10H), 5.16 (d, J = 12.7 Hz, 1H), 5.12 (d, J = 13.1 
Hz, 1H), 4.53 – 4.45 (m, 2H), 4.22 – 4.16 (m, 1H), 4.10 – 4.05 (m, 1H), 3.81 – 3.74 (m, 2H), 
3.71 – 3.64 (m, 1H), 3.61 (dd, J = 12.0, 7.0 Hz, 1H), 3.47 (dd, J = 12.2, 4.4 Hz, 1H), 2.26 – 2.19 
(m, 1H), 1.72 – 1.64 (m, 1H).  
 
13
C NMR (125 MHz, CDCl3) δ 128.82, 128.76, 128.42, 128.36, 128.27, 128.15, 128.05, 127.93, 
127.84, 127.60, 76.50, 71.38, 71.10, 67.59, 66.72, 66.18, 59.98, 59.78, 52.98, 34.62. 
 
HRMS (ESI) m/z calc’d for C20H23NO4Na ([M+Na]
+
) 364.1525, found 364.1518. 
 
 
Compound 3.12: L-4-hydroxyproline methyl ester hydrochloride (3.11, 1.5 g, 8.26 mmol, 1.0 
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eq) and diisopropylethylamine (3.2 mL, 18.37 mmol, 2.2 eq) were dissolved in DCM (40 mL) at 
0
o
C and stirred for 10 minutes. Benzyl chloroformate (1.4 mL, 9.91 mmol, 1.2 eq) was added to 
the reaction mixture which was left to stir for 6 hours at 0
o
C. The reaction mixture was quenched 
with saturated aqueous solution of ammonium chloride (30 mL) and extracted with DCM (2 x 50 
mL). The combined organic fractions were washed with deionized water (30 mL) and brine (30 
mL), dried over Na2SO4, and concentrated via rotary evaporation. The product was purified via 
silica column chromatography (Rf = 0.42 in 3:1 ethyl acetate:hexanes) to yield compound 3.12 as 
clear oil (2.169 g, 94%). 
 
1
H NMR (500 MHz, CDCl3) δ 7.38 – 7.29 (m, 5H), 5.20 – 5.04 (m, 2H), 4.56 – 4.48 (m, 2H), 
3.77 and 3.56 (s, 3H), 3.73 – 3.61 (m, 2H), 2.37 – 2.26 (m, 1H), 2.14 – 2.07 (m, 1H). 
 
13
C NMR (125 MHz, CDCl3) δ 173.58, 155.00, 136.43, 128.68, 128.31, 128.06, 70.22, 69.44, 
67.62, 58.01, 55.45, 54.88, 52.44, 39.33, 38.61. 
 
HRMS (ESI) m/z calc’d for C14H17NO5Na ([M+Na]
+
) 302.1004, found 302.1007. 
 
 
Compound 3.13: Secondary alcohol 3.12 (350 mg, 1.25 mmol, 1.0 eq) was dissolved in dry 
THF (5 mL), followed by addition of sodium hydride (60 mg, 60% dispersion in mineral oil, 
1.50 mmol, 1.2 eq) at 0
o
C. The solution was left to stir for 15 minutes. Benzyl bromide (0.18 mL, 
1.50 mmol, 1.2 eq) and tetrabutylammonium iodide (19 mg, 50.1 μmol, 0.04 eq) were added to 
the reaction mixture, which was left to stir for an addition 1 hour at 0
o
C. The reaction was 
allowed to warm up to room temperature and stirred for an additional 1 hour, upon which it was 
diluted with ethyl acetate (5 mL) and washed with water (5 mL) and brine (5 mL). The organic 
fraction was dried over Na2SO4 and concentrated via rotary evaporation. The product was 
purified via silica column chromatography (Rf = 0.45 in 4:6 ethyl acetate:hexanes) to yield 
compound 3.13 as pale-yellow oil (151.6 mg, 33%). 
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1
H NMR (500 MHz, CDCl3) δ 7.38 – 7.18 (m, 10H), 5.22 – 5.00 (m, 3H), 4.56 – 4.42 (m, 3H), 
4.24 – 4.17 (m, 1H), 3.76, 3.67, and 3.54 (s, 3H), 3.71 – 3.64  (m, 1H), 2.47 – 2.38 (m, 1H), 2.13 
– 2.06 (m, 1H).  
 
HRMS (ESI) m/z calc’d for C21H24NO5 ([M+H]
+
) 370.1649, found 370.1658. 
 
 
Compound 3.14: Boc-protected L-alanine (3.8, 1.60g, 8.48 mmol, 1.0 eq) was added into a 
solution of alcohol 3.9 (1.33 mL, 8.48 mmol, 1.0 eq) dissolved in DCM (16.8 mL), followed by 
addition of EDAC hydrochloride (1.95 g, 10.2 mmol, 1.2 eq) and DMAP (104 mg, 0.851 
mmol, .10 eq). The reaction mixture was left to stir at room temperature for 23 hours, then 
diluted with ethyl acetate (100 mL) and washed with saturated aqueous solution of sodium 
bicarbonate (3 x 100 mL) and brine (2 x 100 mL). The organic layer was collected, dried over 
Na2SO4, and concentrated via rotary evaporation. The product was purified via silica column 
chromatography (Rf = 0.95 in 100% ethyl acetate) to yield compound 3.14 as clear oil (2.15 g, 
84%). 
 
1
H NMR (500 MHz, CDCl3) δ 5.05  (bs, 1H), 4.35 – 4.27 (m, 1H), 4.07 (dd, J = 10.9, 5.8 Hz, 
1H), 4.01 (dd, J = 10.9, 5.6 Hz, 1H), 1.67 (ttt, J = 6.0, 5.8, 5.8 Hz, 1H), 1.44 (s, 9H), 1.38 (d, J = 
7.2 Hz, 3H), 1.35 – 1.23 (m, 8H), 0.89 (t, J = 6.6 Hz, 6H). 
 
13
C NMR (125 MHz, CDCl3) δ 212.31, 107.83, 68.26, 49.50, 37.08, 33.73, 33.68, 28.59, 20.08, 
19.12, 14.60. 
 
HRMS (ESI) m/z calc’d for C16H31NO4Na ([M+Na]
+
) 324.2151, found 324.2146. 
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Compound 3.15: Adenosine 5’-monophosphate morpholidate 3.4 (20 mg, 28.2 μmol, 1.3 eq, 
from Sigma-Aldrich A1127-1G) was dissolved in anhydrous pyridine (0.22 mL), followed by the 
addition of a solution of phosphoramidate 3.5 (26 mg, 36.6 μmol, 1.3 eq) in anhydrous pyridine 
(0.22 mL). 5-ethylthio-1H-tetrazole (11 mg, 84.5 μmol, 3.0 eq) was added to the solution and left 
to stir with the reaction mixture at room temperature for 16 hours. The solvent was removed via 
rotary evaporation and the product was purified via C-18 chromatography to yield pyrophosphate 
3.15 as a white foamy solid (15 mg, 58%). 
 
1
H NMR (500 MHz, CD3OD) δ 8.52 (s, 1H), 8.19 (s, 1H), 7.40 – 7.20 (m, 10H), 6.09 (d, J = 7.5 
Hz, 1H), 5.13 – 5.09 (m, 1H), 4.53 – 4.38 (m, 3H), 4.20 (dd, J = 10.9, 5.7 Hz, 2H), 4.10 (dd, J = 
10.9, 5.6 Hz, 2H), 3.73 (dd, J = 5.7, 3.8 Hz, 2H), 3.40 (dd, J = 5.7, 3.7 Hz, 2H), 2.32 – 2.16 (m, 
2H), 1.96 – 1.90 (m, 2H), 1.85 – 1.79 (m, 2H), 1.53 (d, J = 7.1 Hz, 3H), 1.40 – 1.25 (m, 8H), 
0.93 – 0.86 (m, 6H). 
 
13
C NMR (125 MHz, CD3OD) δ 212.60, 163.91, 143.22, 141.65, 128.75, 128.39, 128.33, 
128.30, 128.25, 128.22, 128.06, 127.92, 127.86, 127.82, 127.54, 127.51, 127.49, 127.46, 127.43, 
125.27, 120.38, 120.35, 120.31, 76.65, 71.25, 67.54, 67.31, 67.19, 56.42, 52.43, 48.38, 48.33, 
35.19, 33.97.  
 
31
P NMR (202 MHz, CD3OD) δ -1.10, -1.79, -10.67. 
 
HRMS (ESI) m/z calc’d for C41H56N7O14P2 ([M]
-
) 932.3360, found 932.3340. 
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3.4.2. Biological experiment 
HINT-1 masking group cleavage experiment  The HINT-1 cleavage assay was carried out 
according to protocols adopted by Bieganowski and co-workers.
14
 Five 1 mL tubes were 
prepared with 50 µL reaction mixtures containing HINT-1 activity buffer (20 mM Na-PIPES, 0.5 
mM MgCl2) and substrate 3.3 (50 µM). The following treatments were implemented to each tube: 
Tube 1: 1 µg of HINT-1; tube 2: 0.33 µg of HINT-1; tube 3: 0.1 µg of HINT-1; tube 4: 0.033 
µg of HINT-1; tube 5: No enzyme. The tubes were incubated at 37
o
C for 5 hours then analyzed 
via LC/MS. 
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3.4.3. Spectra 
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